Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Britain Courts Anthropic Amid US Defense Department Dispute 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
CAMBRIDGE, Mass., Aug. 03, 2017 -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Joseph A. Yanchik III, President and CEO, will present at the Canaccord Genuity 37th Annual Growth Conference.
Conference Details:
| Event: | Canaccord Genuity 37th Annual Growth Conference | |
| Date: | Thursday, August 10, 2017 | |
| Time: | 8:30 AM EDT | |
| Location: | Boston, MA |
A live webcast of the presentation may be accessed from the Events & Presentations section of Aileron’s website. An archived version of the webcast will be available for replay following the event.
About ALRN-6924
ALRN-6924 is a first-in-class product candidate designed to reactivate wild type p53 tumor suppression by disrupting the interactions between the two primary p53 suppressor proteins, MDMX and MDM2. Aileron believes ALRN-6924 is the first and only product candidate in clinical development that can equipotently bind to and disrupt the interaction of MDMX and MDM2 with p53. Based on preclinical data and preliminary evidence of safety and anti-tumor activity in its ongoing clinical trials, there may be a significant opportunity to develop ALRN-6924 as a monotherapy or combination therapy for a wide variety of solid and liquid tumors. ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of acute myeloid leukemia (AML), advanced myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma (PTCL). For information about its clinical trials, please visit www.clinicaltrials.gov.
About Aileron Therapeutics
Aileron is a clinical-stage biopharmaceutical company advancing stapled peptides, a novel class of therapeutics for cancers and other diseases. Stapled peptides are chemically stabilized alpha-helical peptides that are modified to improve their stability and cell penetrability while maintaining high affinity for large protein surfaces. Our goal is to use our proprietary stapled peptide drug platform to create first-in-class therapeutics, like ALRN-6924, that may be able to address historically undruggable targets and complex mechanisms that underlie many diseases with high unmet medical need. Our platform enables us to chemically stabilize and improve the performance and activity of a broad range of alpha-helical peptides that can potentially activate and inhibit key cellular functions that are otherwise difficult to target with existing drug technologies, including small molecules and monoclonal antibodies. For more information, visit www.aileronrx.com.
Source: Aileron Therapeutics
Media: BMC Communications Brad Miles, 646-513-3125 [email protected]
